Waldmann TA - Search Results

1

Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases.

Guex-Crosier Y, Raber J, Chan CC, Kriete MS, Benichou J, Pilson RS, Kerwin JA, Waldmann TA, Hakimi J, Roberge FG. Guex-Crosier Y, et al. Among authors: waldmann ta. J Immunol. 1997 Jan 1;158(1):452-8. J Immunol. 1997. PMID: 8977222

2

Mik-beta 1(Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the beta-chain of the IL-2 receptor.

Kreitman RJ, Schneider WP, Queen C, Tsudo M, Fitzgerald DJ, Waldmann TA, Pastan I. Kreitman RJ, et al. Among authors: waldmann ta. J Immunol. 1992 Oct 15;149(8):2810-5. J Immunol. 1992. PMID: 1401913

3

The interleukin 2 receptor (IL-2R): the IL-2R alpha subunit alters the function of the IL-2R beta subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R alpha subunit.

Grant AJ, Roessler E, Ju G, Tsudo M, Sugamura K, Waldmann TA. Grant AJ, et al. Among authors: waldmann ta. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2165-9. doi: 10.1073/pnas.89.6.2165. Proc Natl Acad Sci U S A. 1992. PMID: 1549576 Free PMC article.

4

Immune receptors: targets for therapy of leukemia/lymphoma, autoimmune diseases and for the prevention of allograft rejection.

Waldmann TA. Waldmann TA. Annu Rev Immunol. 1992;10:675-704. doi: 10.1146/annurev.iy.10.040192.003331. Annu Rev Immunol. 1992. PMID: 1590999 Review.

5

Lymphokine receptor-directed therapy: a model for immune intervention in leukemia, autoimmunity, and immunodeficiency.

Waldmann TA. Waldmann TA. Clin Immunol Immunopathol. 1991 Nov;61(2 Pt 2):S37-46. doi: 10.1016/s0090-1229(05)80036-4. Clin Immunol Immunopathol. 1991. PMID: 1934612 Review.

6

Lymphokine receptor-directed therapy: a model of immune intervention.

Waldmann TA, Grant A, Tendler C, Greenberg S, Goldman C, Bamford R, Junghans RP, Nelson D. Waldmann TA, et al. J Clin Immunol. 1990 Nov;10(6 Suppl):19S-28S; discussion 28S-29S. doi: 10.1007/BF00918688. J Clin Immunol. 1990. PMID: 2081786 Review.

7

Selective elimination in vitro of alloresponsive T cells to human transplantation antigens by toxin or radionuclide conjugated anti-IL-2 receptor (Tac) monoclonal antibody.

Kozak RW, Fitzgerald DP, Atcher RW, Goldman CK, Nelson DL, Gansow OA, Pastan I, Waldmann TA. Kozak RW, et al. Among authors: waldmann ta. J Immunol. 1990 May 1;144(9):3417-23. J Immunol. 1990. PMID: 2139454

8

IL-2-PE40 prevents the development of tumors in mice injected with IL-2 receptor expressing EL4 transfectant tumor cells.

Kozak RW, Lorberboum-Galski H, Jones L, Puri RK, Willingham MC, Malek T, Fitzgerald DJ, Waldmann TA, Pastan I. Kozak RW, et al. Among authors: waldmann ta. J Immunol. 1990 Oct 15;145(8):2766-71. J Immunol. 1990. PMID: 2212661

9

Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders.

Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, Schneider WP, Queen C. Junghans RP, et al. Among authors: waldmann ta. Cancer Res. 1990 Mar 1;50(5):1495-502. Cancer Res. 1990. PMID: 2406013

10

The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts.

Waldmann TA, Goldman CK. Waldmann TA, et al. Am J Kidney Dis. 1989 Nov;14(5 Suppl 2):45-53. Am J Kidney Dis. 1989. PMID: 2683757 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

654 results

Search Page

Filters